The influence of age on the pharmacokinetics of verapamil.
The influence of age on the pharmacokinetics of verapamil at steady state has been studied in 74 individuals, age range 19-79 years, including healthy normotensive volunteers and patients with essential hypertension. The peak plasma concentrations (Cmax) of verapamil were significantly higher in older subjects (r = 0.24; P = 0.03) and there was a non-significant age-related decrease in clearance/F and a non-significant increase in elimination half-life. These results suggest that increasing age is associated with changes in the pharmacokinetics of verapamil but these changes are small and unlikely to be of clinical significance.
Ahmed
J H
JH
University Department of Medicine and Therapeutics, Stobhill General Hospital, Glasgow, Scotland, UK.
Meredith
P A
PA
Elliott
H L
HL
D000328:Adult; D000368:Aged; D000375:Aging / Q000378:metabolism*; D001835:Body Weight / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006207:Half-Life; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D013223:Statistics as Topic; D014700:Verapamil / Q000031:analogs & derivatives / Q000097:blood / Q000493:pharmacokinetics*; D014838:Volunteers
C016904:norverapamil; D014700:Verapamil